Mash-Hud is a qualified patent attorney who is experienced in drafting and prosecution work in semiconductor technologies, opto-electronics, mobile telecommunications, software, medical devices and oil well technology. He also has experience at opposition proceedings before the EPO.

After completing a BSc degree with first class honours in Electronics and Computing, Mash-Hud moved to the University of Cambridge where he gained an MPhil and PhD in Solid State Engineering. Mash-Hud's MPhil research was directed to modelling novel power devices for emerging technologies. He then carried out further research for his PhD on silicon-on-insulator (SOI) based high voltage devices for power ICs and nanoscale transistors using silicon nanowires.

Mash-Hud joined Marks & Clerk in 2008 and qualified as a European Patent Attorney and UK Chartered Patent Attorney in 2013. Mash-Hud has been recognised as a rising star by Managing Intellectual Property, IP Stars, 2017 and 2018.

Doctor in Behavioral Sciences, coach-trainer and professional musician.

Eija is currently the CEO and co-founder of an awarded applied games start up called Altogame. Altogame is a game-changing virtual multiplayer environment for innovation, collaboration and training simulations.

Prior to founding Altogame, Eija developed an internationally unique face-to-face coaching method integrating musicians ́ professional top performance and well-being. She wrote the first Finnish coaching related doctoral thesis on the subject, and the first white paper on how to transform organizations by using arts-derived interventions. Eija has created and run programs on how to integrate agility, innovation and top performance in numerous organizations including Nokia, Kone, UCL, Aalto University, and Anglia-Ruskin University. She is very experienced as public speaker, coach and trainer. The first part of her professional career Eija was an internationally performing musician.

In regard to start-up scenes and communities, Eija has been a start-up member of numerous accelerators/hubs and participated various programs. She has herself acted as a mentor and delivered training to start-ups e.g. in Aalto University and University of the Arts Helsinki (Finland). In addition to the business subjects, her training has included also Human Factor themes such as working with customers (e.g. to understand the real problem), pitching to different audiences (e.g. from academic to corporate, customer or investor viewpoint and language), top performing (multi-cultural, cross-disciplinary etc.) teams, creativity at work, self-leadership, persuasion skills and performing under pressure.

Currently Eija is based in Cambridge, UK.

Bioinformatics scientist specialised in genome analysis with 15 years of experience in software development and project management. Fiona left her job at Illumina Cambridge in 2013 to pursue her vision of enabling efficient genomic data sharing and founded the charity DNAdigest. In August 2014 she founded Repositive as a spin out of DNADigest.

Keywords:
- social enterprise and social impact
- business model development
- software products
- selling to biopharma and CROs
- raising funding
- strategic partnerships

Matthew specialises in the fields of electronics, mobile telecommunications, software and mechanical devices. He has experience in the drafting, filing and prosecution of patent applications in the UK, Europe, USA, Asia, and other jurisdictions across the world.

Having been awarded the prize of Young Electronic Designer of the Year Award in 2002, Matthew then went on to graduate from Leeds University with a first class Master’s Degree in Electronic Engineering. Matthew joined the patent profession in 2008 working for a London based firm of patent & trademark attorneys. Matthew qualified as a European Patent Attorney in 2012 and a UK Chartered Patent Attorney in 2013. He joined Marks & Clerk in 2015.

Katarzyna joined the IMED Oncology team at AstraZeneca as a Drug project Information Manager, taking responsibility for scientific information management governance. In this role Katarzyna oversees and aligns scientific communication strategies with the oncology business acumen.
Prior to this role, she worked for an emerging Clinical Research Organisation in Cambridgeshire, being accountable for clinical project management and cultivating relationships with key business partners. At Amgen, she conducted a business insight project to evaluate market share.

Katarzyna is passionate about oncology and neuroscience R&D, though encouraging open innovation knowledge transfer, scientific communications. Her area of interest lies in the new applications of AI technologies in Healthcare. For the past few years, she has enjoyed gaining experience working both with small businesses and start-ups in the UK, and also global organisations (the Alzheimer’s Society, WHO, and the United Nations internationally.

Katarzyna completed her MSc in Clinical Drug Development and Management at the Queen Mary University/UCL, focused on clinical research recruitment strategies. She holds a BSc degree in Biomedicine and an Eng. degree in Pharmaceutical Technology. As a part of the Erasmus exchange programme she collaborated with the Max Planck Institute for Innovation and Competition in Munich, and the Uppsala University where she focused on pharmaceutical IP innovation.

Dr Karolina Zapadka is a co-founder and Managing Director at ZapaBio Ltd, a global consulting company which aims to support Bioscience Innovation. Her interests lie in the life sciences and healthcare industry and the interface between business and science, entrepreneurship and technology transfer.

Karolina has a strong interest in knowledge exchange and in facilitating collaborations between Academia, Industry and Government. As such she joined the Oxbridge Biotech Roundtable (OBR) in 2013 as President of Cambridge Chapter, where she was highly involved in organising workshops and seminars, as well as setting up and marketing of the OneStart competition. For the past almost eight years she has been actively involved in Cambridge ecosystem, first working in an emerging biotech company (Arecor Ltd.), later during her PhD and postdoc in non-profit organisations. She is a founding member and a former Executive Team Member of Global Innovation Forum Ltd (IF), a global, interdisciplinary network of young researchers, industry
professionals and policy makers. Moreover, she participated in many entrepreneurship courses run by Cambridge Judge Business School including: BioInno Entrepreneurship Course in 2014, a Life Sciences Start-up Weekend with AstraZeneca in 2015, Accelerator Programme, Ignite 2016 & 2017.

She has over nine years of professional experience in research work in both academia and the industry. Her academic work includes a double research Master diploma from Jagiellonian (Poland) and Lund (Sweden) University, PhD from Cambridge (UK) and Postdoctoral work between University of Cambridge and MedImmune. Her research interests are focused on diabetes, drug discovery, stability and formulations of peptide pharmaceuticals.

Dr John Carrigan has a strange job of Chief scientist and innovation (investment opportunity) seeker for SOSV (Sean O Sullivan Ventures), one of the worlds most active early stage investors. His principal interests within the firm are bioscience investments which are developed in RebelBio, a dedicated investment program recently established by Dr Carrigan and his team at Imperial College White City. Dr Carrigan began his career as an academic biochemist where he published papers concerning protein chemistry and metabolomics. Subsequently he into the world of start ups with Dublin based AERBIO, which was acquired by green biochemical company Cellulac ltd in 2013. Away from his work with SOSV, he acts as an expert advisor for the European Innovation Council's SME (Small Medium Enterprise) instrument. An initiative to fund the most promising start up bioscience companies across Europe.

Philippa is a Licensing and Ventures Manager at Oxford University Innovation (OUI) in the Digital Health and Medical Devices team. She has worked for the past three years with researchers across the University of Oxford to help them create impact with their ideas. Philippa has expertise in developing early stage ideas into business propositions, which includes IP landscape analysis, market analysis, building business plans, CE marking and regulatory issues, advice on app development, and licence negotiations. Whilst a large number of her projects are in the digital health space, Philippa has facilitated spinout companies from the Humanities and Social Sciences Divisions. She is delighted to be increasingly working with projects focused on mental health issues.

Philippa also has a passion for social enterprises, companies that put purpose before profit, and is part of the team offering a support to create these entities from the University. Philippa was part of the team that set up OxReach, the crowdfunding platform for social good projects from the University of Oxford. She has supported four successful campaigns which have all benefited substantially from the public support that they received and are now creating local and international impact

David is a social entrepreneur and experienced technologist with a passion for innovation in healthcare and specifically paediatrics. He has had a career with IBM spanning nearly 20 years and has spent the last three years working within IBM’s artificial intelligence arm, Watson. David began the role of Innovation and AI Lead at the beginning of 2018 with the remit of exploring new ways for healthcare organisations to embrace IBM’s healthcare and Cognitive technologies.

Outside of IBM, David runs a UK based children’s charity, Thinking of Oscar, which supports children and their families whilst in hospital care, funding innovation and technology over and above that provided by the UK health services. Thinking of Oscar was set up following the sudden death of his son Oscar in 2014 and has raised over £200,000. David and his wife Hannah work closely with UK Children’s hospitals to identify projects where they can make a difference. David is a member of The International Society for Paediatric Innovation (iSPI) which has been formed to address the unmet needs of an open global network, enabling unique opportunities for paediatric leaders to be at the cutting edge of technological innovations. His ultimate goal is to see artificial intelligence technologies, such as Watson, pervasively used in paediatric healthcare to assist with knowledge share, decision making and ultimately save lives.

David is a ‘Digital Health Expert in Residence’ at the University of Oxford supporting it’s healthcare start-up incubator, The Hill. David is also an advisor to a number of boards and faculties looking at health technology, child health and the future of medicine. David lives in rural Oxfordshire in the UK, with his wife and 3 young children. David is a keen triathlete, cricketer and wine enthusiast, holding an Advanced Level 3 qualification from the Wine and Spirit Education Trust. He is building up to compete in his first full Ironman in July 2019.

Nick is an NHD Trust Digital Innovation & Population Health Lead, a startup entrepreneur and co-founder of health innovation lab. He has a background as a neurosurgeon with over 15 years of front line clinical experience in the NHS.

Tony Hart is the Head of Smart Oxford, Oxford’s smart city project.

Tony has been working with technology innovation companies and start-ups across Oxfordshire and the UK for the past 15 years, having worked for and with major technology companies in the US, Europe, India and China. Recently he was the Managing Director of the UK subsidiary of Holley Technology, the leading Chinese smart meter manufacturer based in Hangzhou.

He has a strong focus and ability at identifying and bringing to market (commercialising) technology solutions within both corporate and entrepreneurial (start-up) environments.

Tony has an MA in Engineering & Economics from the University of Oxford and an MBA from Henley Management School.

In a school essay entitled “What do you want to be when you grow up” – I explained why I wanted to be a Judge, things don’t always turn out the way we want them to – sometimes the exceed our imagination. Many years later, I received an invitation to join the Design Council as a Judge on the Tech Spark competition. Reviewing amazing pitches from innovative start-ups and helping to select those with the qualities to succeed. It was a privilege to be involved and fuelled my long time ambition!

As Managing Director of Triteq, a product design consultancy, I am continuously connected to new ideas, creative talent and amazing people. I learn every day.

As a NED, I work with Intelligent Horsemanship, a company that helps horses and their humans to get the most out of their relationships. Kelly Marks, the Founder, taught me to ride racehorses and trained me to deal with the challenges of a horse riding trip across the Mongolian Steppes.
I am currently planning my next adventure.

Brian has had a long and successful career as medtech business leader in large corporations, AIM listed companies and early stage ventures. He was CEO of Lombard Medical Technologies (2005 – 2009) and General Manager of Boston Scientific in UK (1999 – 2005). Brian is currently a board member of three emerging medtech companies, including Oxford Endovascular.

Sarah has inspired others to achieve leadership performance through theatre teaching, psychotherapy, coaching and training for the past 40 years. She has worked with teenagers, adults, ex-prisoners and senior executives.

These days, as well as being co-founder of STEMM Commercial, Sarah trains and coaches leaders with a STEMM background to win influence, advancement and stakeholder buy-in. She works in not-for-profit organisations such as the Stockholm Environment Institute as well as in commercial organisations such as Cisco, Skanska and Astrium (EADS) and SMEs. In partnership with Oxford University’s Institute of Biomedical Engineering, she has designed and delivered programmes for STEMM doctoral researchers to attract engagement and buy-in at conferences, develop business awareness and improve their interview skills to advance their innovation.

James has worked with a variety of largely corporate clients, including start-ups, SMEs, international companies and groups, and publicly listed companies. James has experience working in a wide range of sectors but with particular emphasis on science / technology companies. He has worked closely with entrepreneurs, academics, research institutions and companies from spin out through to listing on accounting, taxation and strategic issues. He is delighted to offer advice and guidance for the programme.

With offices in the South of England, membership of Kreston International and a global network of independent accountants and business advisers, James Cowper Kreston is ideally placed to provide informed local, national and international advice.

Paul Rous has over fifteen years’ experience as an entrepreneur, investor and active supporter of early stage businesses. His professional background spans the military, tourism, hospitality, finance, asset management and technology. He has worked with Goldman Sachs, Freeman, Imperial Innovations, and Generation Asset Management a $1.4billion asset management business. Paul co-founded Fuel Ventures, a London-based seed venture capital fund and active accelerator focusing on early stage digital businesses, which he exited in 2016.

Marc is an economic sociologist in the Strategy, Innovation and Marketing Faculty at Saïd Business School and a Governing Body Fellow of Wolfson College. His teaching focuses on strategy and innovation, implementation, and entrepreneurial leadership and leadership for complex operations. At Oxford, he is Academic Director for the Science Innovation Plus initiative, support many student and research activities for the Skoll Centre for Social Entrepreneurship, and serve as a core faculty member for the Goldman Sachs 10K Women Entrepreneurs Programme in China. He is advisor/mentor to five startups founded by recent Oxford alumni, and a strategic advisor for Oxford Entrepreneurs, Global Thinkers Forum, Local Insight/Global Impact, and the Oxbridge Biotechnology Roundtable. He is recently supported an MBA team working with the World Economic Forum Global Agendas Councils. Marc does custom executive education with a range of global firms, public sector organisations, and civil society agencies.

Coordinator of Orkestra's Crecer+ Investor Network, Mentor on the GAZTENPRESA mentoring programme with the YBI methodology.

An entrepreneur and CEO of a bio-science firm that she founded in 2004, she previously worked as an Executive Assistant for 10 years in a firm focusing on financial intermediation with high political risk countries.

She holds a Bachelor's degree in Law, from the University of Deusto. She also completed an Advanced Management Programme at IE and a holds a Master's degree in International Business Management at EOI (industrial organisation school).

Tontxu Campos holds a Ph.D. in Economics and Business Science. Thesis Title: “Cultura empresarial en los libros de texto” Cum laude at the University of Deusto. Master in Advanced Management and a Bachelor in Economics and Business Administration at the University of Deusto.

Jose Antonio Campos Granados combines his responsibilities as the Director of Deusto Entrepreneurship Centre, and as a Professor of Deusto Business School in the Faculty of Engineering. His work has been linked to education, innovation and entrepreneurship. He has work experience in the public sector, private companies, NGOs and education. Particularly noteworthy is his work as the Minister of Education, Universities and Research of the Basque Government for four years. As part of his responsibilities he developed and introduced the integrated curriculum in the Basque Country, focusing on students’ competency development from 0 to 18 years and in vocational training.

As part of his knowledge in the field of the transition from the educational to the labour market, it should be noted that Dr. Campos held the position of Provincial Minister of Innovation and Economic Development, where he developed entrepreneurship policies to foster innovative start-ups creation as part of the economic recovery process.

Dr. Castellana holds a Bachelor’s Degree in Biological Sciences from the University of Lecce, IT and a PhD in Cellular and Molecular Biology from the University of Strasbourg, FR. His scientific specialities span from oncology, inflammation and immunology in animal systems, and stem cell regeneration in mouse skin. He has been awarded with competitive grants for research projects (AECC, ES and Ligue Contre le Cancér, FR). He has published original articles and reviews in international journals with high impact in the press and acted as evaluator of original articles in pathology and cancer fields.

Dr. Castellana has been the founder and spokesperson of the PostDoc Association at CNIO, Madrid, ES. He also holds an MBA from Aliter International Business School, Madrid, ES, and specialized courses in marketing and valorisation of academic breakthroughs from INSEAD, FR and IE Business
School, Madrid. He collaborates in medtech projects (oncology and neurology from MIT Boston and UPM, Madrid) dragging academic knowledge and ideas to commercial value. Since 2016 he has been Life Science specialist Collaborator at Ventac Partners - a Venture Builder and VC private fund. From
February to September 2017 was appointed as Head of Operations at mVision Foundation, Madrid. He is also an independent new business strategy consultant and participates in presenting SME’s projects to European Commission funding for SMEs instruments (H2020).

Since October 2017 he has been Head of Technology Transfer at CIC bioGUNE, Bilbao to scout for viable business projects and develop valuable business development activity and launch of new entrepreneurial biomedical projects.

I have a scientific background (Physical Chemistry, PhD), having worked for 10 years in the UK (Cambridge) and the USA (Los Angeles). Later, I worked for 20 years in a Technology Centre (Tecnalia), mostly in international projects with USA partners (Otis, Carrier, Pratt & Whitney, Sikorsky, Boeing, Praxair). Some of those projects led to the creation of spin-off companies with proprietary (patented) technologies. I was involved in the management of a few of them and, after achieving market success, in negotiating their sale to larger companies. Through this activity, I gained knowledge and experience in technology transfer transactions, with a particular focus on creating business value by negotiations and by managing intellectual property (IP) as a key element of the business strategy.

Now, I work mainly with entrepreneurs, start-ups and technology based SMEs, helping them to find routes from ideas, to market success and, eventually, to lead market segments. As a business coach, my work is mostly about asking challenging questions to gain insight. My scientific background has trained me to search for evidence, to be sceptical in absence of data, but also to find ways through. In many cases my work deals with helping the entrepreneurs to transition from “uninformed optimism”, through “informed pessimism”, to reach an “informed optimism” position.

In recent years I have been active as a Business Angels, seeking for opportunities to invest and participate in the management of technology based start-ups with strong IP positions.

As a Computer Engineer from Deusto University, I have developed my professional career working for different software companies.
In May 2008 I joined the Init Group as a Project Director.

Currently, I am the Technical and Commercial Director of Init Health and partnership program manager of our Init Health Affinity and Wellness Corporate platforms.

Since May 2017 I have been a teaching team member of the Expert Course in Management of Healthy Companies organized by Sánchez-Toledo & Asociados.

In September 2016, I founded Health 2.0 Basque, a community with the objective of leading the e-Health ecosystem in Euskadi, within the international Health 2.0 movement, which emerged in 2007 in San Francisco, to promote entrepreneurship and the use of new technologies in health.

With an experience of more than 25 years in commercial positions (20 of them in the insurance sector), since 2011 I have been Director of Business Development at Init Health, the health area of Init Group. Our main asset is the health and wellness platform Inithealth, established in different national and international companies that can associate their brand with concepts such as health, technology and innovation.

Since May 2017 I have taken part in the teaching team of the Expert Course in Management of Healthy Companies organized by Sánchez-Toledo & Asociados.

In September 2016, with Gonzalo López, Commercial Technical Director of Init Health and Blanca Usoz, specialist in Occupational Medicine, I founded Health 2.0 Basque, a community the aim of which is leading the eHealh ecosystem in Basque Country. We are within the international Health 2.0 movement, created in 2007 in San Francisco, to promote entrepreneurship and the use of new technologies in health.

Chibeza Chintu Agley holds a first-class BSc (Hons), and the University Prize, from Brunel University; as an undergraduate he was co-founder of a cloud platform for students to share and consume information about University life. Chibeza went on complete an MSc (with Distinction and Colt Prize) and then PhD from King’s College London in physiology and adult stem cell biology respectively. For his PhD thesis Chibeza was awarded the Tadien Rideal Prize for outstanding doctoral research in molecular science. After finishing his PhD, Chibeza began his postdoctoral work at the Cambridge Stem Cell Institute and was soon after appointed to the position of 'Research Fellow in Genetics' at Homerton College, University of Cambridge. During this time Chibeza co-founded CamBioScience Limited with two other colleagues from the University of Cambridge. CamBioScience went on to develop an Artificial Intelligence powered enterprise EdTech platform called OBRIZUM® that allows managers in high-skill areas to automatically create and deliver adaptive eLearning and eAssessments. The OBRIZUM® platform in poised to disrupt the professional education system and transform the trading of content between organizations. The platform is built to overcome the content, cost, scale and efficiency challenges of providing learning and development opportunities to a globally distributed workforce or student, or customer base. OBRIZUM’s adaptive course creation and analytics tools are available to enterprises via PaaS and SaaS based subscription models.

David has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College, London and three years of post-doctoral experience. David has worked in the pharmaceutical industry for almost 20 years. He worked in big pharma at AstraZeneca for more than 17 years in a wide variety of R&D roles both in the UK and the US. Whilst at AstraZeneca he was heavily involved in developing the use of informatics and systems biology to support the development of new medicines. David joined Blueberry Therapeutics as Chief Scientific Officer at the start of 2014. In this role, he is responsible for leading the research activities of the business which are focused on developing new treatments for serious infectious diseases. The first of these treatments has now entering clinical testing.

Martin Eglitis, Ph.D., has over 15 years research experience and additionally 20 years of pharmaceutical licensing experience. He has headed labs at the NIH, lead discovery and enablement research teams at a biotech startup, and conducted all aspects of the licensing process at global pharmaceutical companies. Dr. Eglitis has closed licensing deals valued into the hundreds of millions of dollars. Currently at Blazing Star Pharma Advisors, he provides strategic and business development consulting services to small and mid-size biopharmaceutical companies.

Prior to founding Blazing Star Pharma Advisors, Dr. Eglitis held Senior Business Development postitions at Teva Pharmaceutical Industries Ltd., Amgen Inc., and Eli Lilly and Company. Dr. Eglitis was also involved in one of the first gene therapy start-ups, Genetic Therapy Inc., from its inception through a successful IPO. While there he contributed to the IND filing for the first gene therapy clinical trial.

Dr. Eglitis is inventor on four patents, and author of dozens of research papers and book chapters, spanning a wide breadth of fields including mammalian developmental biology, retroviral vector molecular biology, and physiological responses to neurological disease and injury. He obtained his baccalaureate in Biology and Ph.D. in Anatomy and Developmental Biology from the University of Virginia.

Paul is co-founder and Chief Executive Officer of HairClone, a cell therapy Company developing cell based treatments for androgenic alopecia. Paul has over 30 years’ experience in the US and UK in the commercialisation of various Regenerative Medicine and Cell Therapy products in both public and private Companies. He was the lead inventor on patents for Apligraf the first multi-cell therapy approved by the FDA which has treated hundreds of thousands of patients in the US with chronic ulcers. Paul was the sole founder of Intercytex Ltd. where he served as CEO for the first 5 years. During this period Intercytex developed several products that reached the clinic, including Vavelta which was commercially available and being used for the correction of Rhytids, scar contractures and dystrophic epidermolysis bullosa before the EU’s ATMP regulations came into force. Intercytex also carried out the world's first cell therapy clinical trial to induce new hair formation. Paul has sat on a variety of panels, grant funding bodies and regulatory committees. He is co-editor of the Journal of Regenerative Medicine, a co-Director of the Doctoral Training Centre in Regenerative Medicine at Manchester University and Industrial Director of Regener8.

Joe helps companies in the healthcare, materials and consumer product sectors to protect their innovation and gain a competitive advantage in these sectors. He is a partner, patent attorney and patent litigator at Mewburn Ellis LLP. Joe helps start-ups to FTSE 100 companies manage their IP in order to achieve their commercial goal.

In particular, Joe has more than a decade’s experience protecting inventions in the healthcare sector including new chemical entities (such as protein kinase inhibitors, ADCs, PROTACs, PET imaging agents), formulations (such as oral peptide formulations) and biocompatible materials ( such as stents and implantable electrodes).

Joe particularly enjoys working with enthusiastic start-ups to help with their IP from concept to product launch and beyond. He has mentored and been on the judging panel of business plan competitions and regularly guest lectures at UK universities on the commercialisation of research.
Joe has a degree and PhD in Chemistry from the University of Durham. His diverse research experience includes imaging chromosome aberrations, polymer interdiffusion, supramolecular anion interactions and catalyst recycling constructs.

David is an innovation professional who has spent many years developing and delivering innovation and ideas in a range of different companies. He has a lot of experience in idea management and project delivery and his consulting business provides support in these areas.

Holding a degree in Quality Control of Medicines from the Federico II University of Naples and an MBA from Business School Lausanne, Valentina is a motivated and ambitious professional that works since 11 years in the pharma industry. Valentina spent most of her career in Novartis in roles of increasing responsibilities within quality assurance and manufacturing areas of drug development and commercial business units. After her MBA she decided to join a “start-up like” company focused on multiple therapeutic area as well as orphan diseases, Idorsia where she can contribute to move projects forward from development to the commercial phase.

She is positive, creative and inspiring with the passion for continuous improvement and problem solving.

Traveler. Painter. Art and books lover.

Dr Stewart White, Previously CEO of two life science AIM-quoted companies, CEO of Novel Technologies Holdings Limited, Chairman of Mikota Ltd, Non-Executive Director with The Electrospinning Company Limited, Scientific Advisory Board of Collagen Solutions plc, Visiting Professor at Glasgow University.

Sina Henrichs has broad professional experience in implementation and development of project outlines in the academic environment. She holds a doctorate in Molecular Biology from the University of Zurich as well as an MBA in Academic Management form the University of Basel. Sina Henrichs combines her extensive research experience in the life sciences and in-depth understanding of process development and project management to provide interactive and professional training experiences. She implemented the Graduate Center GRACE, the professional platform for doctoral candidates and postdocs at the University of Basel and is founder of Manage Science (www.managescience.ch). At the moment, Sina is holding a position as Project Manager Education at the AO Foundation in Davos.

Mauro Lattuada works as Technology Transfer Manager at Ecole Polytechnique Federale de Lausanne (EPFL) mainly focused in ICT and engineering areas managing the intellectual property stemming from EPFL research activities and negotiating contracts between laboratories and companies.
Mauro has previously worked for Abilis Systems (acquired by Alitech Inc.) in the semiconductor and digital television business within the Kudeski group and as co-founder of Livetools Technology (now part of the Euro Media Group) a startup to develop digital television transmission systems for worldwide live sports events.

Mauro owns a diploma from the Politecnico di Milano, a doctorate from Ecole Polytechnique Federale de Lausanne and a Master in Intellectual Property Law and Management from the University of Strasbourg.

Sophie is a marketing consultant specialised in medical technologies, currently collaborating with Startups located at the EPFL in Lausanne.

She has 15 years experience in marketing, working in several European countries.

She recently worked for Braun Healthcare, where she was responsible for the re-positioning of the Braun blood pressure monitors category into true consumer-oriented connected solutions, empowering people to feel on top of their heart health. She was also in charge of the development of the pan-European Go To Market Model of this new product range.

Sophie also has a proven track record of working with sales teams, developing strong relationship with key customers throughout Europe, resulting in double-digit growth of the categories she was managing.

As a dynamic marketing professional, she is passionate about technological innovations and enjoys sharing her knowledge and experience with others.

Oliver is a freelance Consultant in the advanced therapies sector, advising organisations on market analysis and all aspects of the innovation cycle for cell and gene therapies. He has published guidance for investors approaching the advanced therapies industry, in addition to other industry-focused reports and updates. Oliver currently Chairs the TERMIS EU Business Plan Competition, an accelerator for tissue engineering and regenerative medicine startups, having previously been a finalist. He completed his Master's degree at King's College London.

Murat Basarir has been involved in a broad spectrum of international cleantech projects, such as launching UK's first wireless charged electric bus startup, part of developing Portugal's first virtual power plant trial and UK's first driverless pod initiative.

Prior to cleantech investments, he has led a nationwide energy efficiency project that has been acknowledged by the Economist, BBC, and has been shown as an exemplary low-carbon initiative by the government.

Murat holds a BSc and MSc in Mechanical Engineering from Queen's University and an MPhil in Engineering from Cambridge University and has completed the Ignite programme at Stanford's Graduate Business School.

Davide Danovi leads the Cell Phenotyping Platform at the Centre for Stem Cells and Regenerative Medicine, King's College London. He holds an MD from University of Milan and a PhD in Molecular Oncology from the European Institute of Oncology where he demonstrated the causative role of the HdmX protein in human cancer. He completed his postdoctoral training working with Prof. Austin Smith and Dr. Steve Pollard at the University of Cambridge and at University College London where he developed a screening platform to isolate compounds active on human neural stem cells from normal or brain tumour samples. Prior to his current role, he worked as principal scientist at a novel biotechnology company founded to isolate drugs for regenerative medicine using innovative stem cell technologies.

Stathis works with Shell Digital Ventures in the development of new products using cutting-edge software technologies. Before joining Shell, he worked in the investment team of HOF Capital in London sourcing new deals. He has previously worked as a sustainability consultant and researcher at Price & Myers for more than 5 years in R&D projects funded by Innovate UK in collaboration with the University of Cambridge. The past 3 years, he was involved in global deep tech accelerators including the Entrepreneur First, the CleanTech Challenge and the Innovation Forum ImagineIF. During his doctorate at UCL, Stathis published extensively in peer-reviewed journals and presented in international conferences. Whilst at UCL, he co-founded a hub to support engineering students in international development and social enterprise ventures in countries such Ethiopia, Timor-Leste, Nicaragua and Rwanda. He is a STEM ambassador and he is involved in the Reload Greece initiative as a mentor.

In his career as a UX designer and researcher, Simon has helped genomic startups define information experiences for their data platforms, collaborated with hospital teams to improve information exchange for clinical genetics, designed funding programs for the European Commission and used community labs to test the usability of handheld genetic sequencers. Simon works as a Designer and Researcher in BioDesign team at Science Practice in London. He has previously worked in both research and diagnostic genetics laboratories, and has degrees in Genetics and Science and Innovation Policy.

Marek is an experienced product designer specialising in user experiences for healthcare and the life sciences.

Marek leads the BioDesign team at Science Practice where he helps life science startups design successful digital products. Previously, he worked at Ctrl Group where he was involved in designing new digital health products for patients, clinicians, and research users. He was also responsible for the early-stage development of the Bento Lab — world's first personal DNA lab.

Marek is also an experienced workshop leader and speaker with previous appearances at the SETI Institute, OpenVis Conf, IEEEVis conferences, and the World Usability Days.